Home/Indications/Oncology/Colorectal Cancer

Colorectal Cancer

Oncology 10 original drugs

Novel Drugs

Reformulations

Drug Targets

Oncology indication. Colorectal Cancer has 10 FDA-approved novel treatments, led by Bristol-Myers Squibb, with 1146 active industry clinical trials across 14 drug targets. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.

Colorectal Cancer Market Leaders

Companies with the most FDA-approved novel Colorectal Cancer drugs.

Phase 3 Readouts Pro

12 active Phase 3 trials with confidence-graded completion dates.

Full calendar →

Q4 2026

Tunlametinib plus Vemurafenib

Shanghai Kechow Pharma, Inc.

Estimated · aging NCT06008119

Q2 2027

XLJDOD compound granule

Jiangsu Famous Medical Technology Co., Ltd.

Estimated · stale NCT05709249

Q2 2027

JMT101

Shanghai JMT-Bio Inc.

Estimated · aging NCT07134205

Unlock 9 more readouts with confidence-graded estimates

Upgrade to Pro

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Colorectal Cancer Treatments by Mechanism

Top 12 mechanisms across 56 industry trials with a known mechanism of action.

See full pipeline →

Kinase Inhibitor

7 trials 3 active 5 sponsors

Programmed Death Receptor-1 Blocking Antibody

8 trials 1 active 4 sponsors

VEGFR-1/VEGFR-2/VEGFR-3

7 trials 1 active 3 sponsors

Vascular Endothelial Growth Factor Inhibitor

6 trials 1 active 3 sponsors

Nucleoside Metabolic Inhibitor

3 trials 1 active 3 sponsors

CTLA-4-directed Blocking Antibody

2 trials 1 active 1 sponsor

AXL/FLT-3/KIT/MER/MET/RET/ROS1/TIE-2/TRKB/TYRO3/VEGFR-1/VEGFR-2/VEGFR-3

2 trials 1 active 1 sponsor

Programmed Death Ligand-1 Blocker

2 trials 1 active 2 sponsors

ALK/ROS1/NTRK1/TRKB/TRKC

1 trials 1 active 1 sponsor

Epidermal Growth Factor Receptor Antagonist

13 trials 6 sponsors

Vascular Endothelial Growth Factor Receptor 2 Antagonist

3 trials 1 sponsor

Poly(ADP-Ribose) Polymerase Inhibitor

2 trials 2 sponsors

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Colorectal Cancer Clinical Pipeline by Phase

810 industry-sponsored trials across 413 sponsors

View full landscape →

Showing 7 of 7 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Takeda	Fruquintinib	VEGFR-1/VEGFR-2/VEGFR-3	RECRUITING	2027-10-04	NCT06562543
Bayer	Regorafenib (Stivarga, BAY73-4506)	—	COMPLETED	2023-03-20	NCT03564938
Roche	5-FU based doublet chemotherapy	—	COMPLETED	2015-04-04	NCT01695772
Norgine	MOVIPREP	—	COMPLETED	2013-01	NCT01689792
Roche	bevacizumab [Avastin]	—	COMPLETED	2011-08	NCT00577031
Medtronic - MITG	—	—	TERMINATED	2013-11	NCT01706822
Myriad Genetic Laboratories, Inc.	—	—	TERMINATED	2012-08	NCT01468623

Showing 89 of 89 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Natureceuticals Sdn Bhd	Nuvastatic 300	—	RECRUITING	2026-10-31	NCT07669454
Shanghai Kechow Pharma, Inc.	Tunlametinib plus Vemurafenib	—	RECRUITING	2026-12-24	NCT06008119
Natureceuticals Sdn Bhd	Nuvastatic™	—	RECRUITING	2027-03-31	NCT07669519
Jiangsu Famous Medical Technology Co., Ltd.	XLJDOD compound granule	—	RECRUITING	2027-04-01	NCT05709249
Jiangsu Simcere Pharmaceutical Co., Ltd.	Suvemcitug injection, trifluridine/tipiracil tablets	—	RECRUITING	2028-01	NCT07361003
Summit Therapeutics	Drug: Ivonescimab Injection	—	RECRUITING	2028-05-31	NCT07228832
Chipscreen Biosciences, Ltd.	Tucidinostat	—	RECRUITING	2028-05-31	NCT06497985
Amgen	FOLFIRI Regimen	—	RECRUITING	2028-09-25	NCT06252649
Incyte Corporation	INCA33890	—	RECRUITING	2028-12-29	NCT07284849
AbbVie	Telisotuzumab adizutecan	—	RECRUITING	2029-05	NCT07525206
GE Healthcare	GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT)	—	RECRUITING	2029-06	NCT07219238
EMD Serono Research & Development Institute, Inc.	Precemtabart tocentecan	—	RECRUITING	2029-10-16	NCT07549412
Bristol-Myers Squibb	Pumitamig	—	RECRUITING	2030-02-02	NCT07221357
Akeso	Cadonilimab (AK104)	—	RECRUITING	2030-06-15	NCT07412613
Qilu Pharmaceutical Co., Ltd.	QL1706	—	RECRUITING	2030-12	NCT06686576
Suzhou Suncadia Biopharmaceuticals Co., Ltd.	Adebrelimab in combination with SHR-8068 and chemotherapy	—	RECRUITING	2032-11	NCT07454720
Shanghai Henlius Biotech	HLX10	—	RECRUITING	2025-09-24	NCT04547166
Shanghai Cingularbio Co. Ltd	—	—	RECRUITING	2025-09-01	NCT06968221
AbbVie	Telisotuzumab Adizutecan	—	ACTIVE NOT RECRUITING	2027-08	NCT06614192
Taizhou Hanzhong biomedical co. LTD	HX008(Pucotenlimab)	—	ACTIVE NOT RECRUITING	2026-06-30	NCT05652894
Exelixis	XL092	—	ACTIVE NOT RECRUITING	2026-05	NCT05425940
Suzhou Suncadia Biopharmaceuticals Co., Ltd.	SHR-A1811	—	ACTIVE NOT RECRUITING	2026-04	NCT06199973
Mirati Therapeutics Inc.	MRTX849	—	ACTIVE NOT RECRUITING	2026-01-16	NCT04793958
Jiangsu HengRui Medicine Co., Ltd.	HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab	—	ACTIVE NOT RECRUITING	2025-12-01	NCT05945901
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Anlotinib hydrochloride capsule	—	ACTIVE NOT RECRUITING	2024-12-31	NCT04854668
Bristol-Myers Squibb	Ipilimumab	CTLA-4-directed Blocking Antibody [EPC]	ACTIVE NOT RECRUITING	2024-08-28	NCT04008030
Shanghai JMT-Bio Inc.	JMT101	—	NOT YET RECRUITING	2027-06-01	NCT07134205
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	TQB2102 Injection	—	NOT YET RECRUITING	2027-08	NCT07483684
Shanghai JMT-Bio Inc.	JSKN003	—	NOT YET RECRUITING	2027-11-30	NCT07384377
Qilu Pharmaceutical Co., Ltd.	QL1706	—	NOT YET RECRUITING	2028-07	NCT07025239
Taizhou Mabtech Pharmaceutical Co.,Ltd	Enlituo®	—	NOT YET RECRUITING	2029-10-01	NCT07595276
Exelixis	Cabozantinib	AXL/FLT-3/KIT/MER/MET/RET/ROS1/TIE-2/TRKB/TYRO3/VEGFR-1/VEGFR-2/VEGFR-3	NOT YET RECRUITING	2030-05-31	NCT07620574
Vaccinogen Inc	OncoVAX and Surgery	—	NOT YET RECRUITING	2031-08	NCT02448173
Immunophotonics, Inc.	1.0% IP-001 for Injection, a 10 mg/mL solution of IP-001 in water	—	NOT YET RECRUITING	2033-12	NCT07321847
Amgen	Sotorasib	KRAS G12C	COMPLETED	2025-07-16	NCT05198934
Merck	favezelimab/pembrolizumab	—	COMPLETED	2024-08-15	NCT05600309
Merck	favezelimab/pembrolizumab	—	COMPLETED	2024-08-15	NCT05064059
Merck	Olaparib	Poly(ADP-Ribose) Polymerase Inhibitor [EPC]	COMPLETED	2023-03-27	NCT04456699
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	Double blind control period A140	—	COMPLETED	2023-03-22	NCT04835142
Isofol Medical AB	Arfolitixorin	—	COMPLETED	2022-11-18	NCT03750786
Hutchison Medipharma Limited	Fruquintinib	VEGFR-1/VEGFR-2/VEGFR-3	COMPLETED	2022-07-29	NCT04322539
Taiho Oncology, Inc.	Trifluridine/Tipiracil	—	COMPLETED	2022-07-19	NCT04737187
Taizhou Mabtech Pharmaceutical Co.,Ltd	CMAB009	—	COMPLETED	2022-05-06	NCT03206151
Takeda	oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab	—	COMPLETED	2022-01-14	NCT02394795
Bristol-Myers Squibb	Nivolumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2021-02-01	NCT03414983
AB Science	Masitinib	—	COMPLETED	2020-12	NCT03556956
Suzhou Zelgen Biopharmaceuticals Co.,Ltd	Donafenib	—	COMPLETED	2020-04-30	NCT02870582
Sumitomo Pharma America, Inc.	Napabucasin	—	COMPLETED	2020-04-28	NCT02753127
Shanghai Henlius Biotech	HLX04 100 mg in 4 ml Injection	—	COMPLETED	2020-04-15	NCT03511963
Pfizer	Encorafenib	—	COMPLETED	2019-02-11	NCT02928224
Jiangsu HengRui Medicine Co., Ltd.	Famitinib	—	COMPLETED	2019-02	NCT02390947
AryoGen Pharmed Co.	Bevacizumab + FOLFIRI-3	—	COMPLETED	2018-07-30	NCT03288987
Roche	Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody	—	COMPLETED	2018-03-09	NCT02788279
Sanofi	AFLIBERCEPT AVE0005	—	COMPLETED	2017-01-31	NCT01571284
Hutchison Medipharma Limited	fruquintinib	VEGFR-1/VEGFR-2/VEGFR-3	COMPLETED	2017-01	NCT02314819
Sirtex Medical	FOLFOX6m	—	COMPLETED	2016-12-23	NCT01721954
Cosmo Technologies Ltd	Methylene Blue MMX®	—	COMPLETED	2016-10	NCT01694966
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Anlotinib	—	COMPLETED	2016-08-18	NCT02332499
Taiho Pharmaceutical Co., Ltd.	TAS-102	—	COMPLETED	2016-02-16	NCT01955837
Merck KGaA, Darmstadt, Germany	Cetuximab	Epidermal Growth Factor Receptor Antagonist [EPC]	COMPLETED	2016-01-25	NCT01228734
Johnson & Johnson	Xilonix	—	COMPLETED	2015-11-30	NCT02138422
Norgine	NER1006, Day Before-Only Dosing	—	COMPLETED	2015-08	NCT02273141
Norgine	NER1006, 2-Day Split-Dosing	—	COMPLETED	2015-08	NCT02273167
Norgine	NER1006	—	COMPLETED	2015-06	NCT02254486
Sanofi	AFLIBERCEPT	Vascular Endothelial Growth Factor Inhibitor [EPC]	COMPLETED	2015-06	NCT01670721
Sanofi	Aflibercept	Vascular Endothelial Growth Factor Inhibitor [EPC]	COMPLETED	2014-10	NCT01661270
Eli Lilly	Ramucirumab	Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC]	COMPLETED	2014-07-17	NCT01183780
Amgen	Panitumumab	Epidermal Growth Factor Receptor Antagonist [EPC]	COMPLETED	2014-06	NCT01412957
Taiho Oncology, Inc.	TAS-102	—	COMPLETED	2014-01-31	NCT01607957
Monsea Ltd.	—	—	COMPLETED	2013-12	NCT01410955
Amgen	Cetuximab	Epidermal Growth Factor Receptor Antagonist [EPC]	COMPLETED	2013-02-05	NCT01001377
Shanghai Zhangjiang Biotechnology Limited Company	CMAB009 plus Irinotecan	—	COMPLETED	2012-12-23	NCT01550055
Amgen	Pegfilgrastim	Leukocyte Growth Factor [EPC]	COMPLETED	2012-09-17	NCT00911170
Roche	Bevacizumab	Vascular Endothelial Growth Factor Inhibitor [EPC]	COMPLETED	2012-05	NCT00623805
AEterna Zentaris	Capecitabine	Nucleoside Metabolic Inhibitor [EPC]	COMPLETED	2012-04	NCT01097018
Bayer	Regorafenib (Stivarga, BAY73-4506)	—	COMPLETED	2011-07	NCT01103323
Braintree Laboratories	BLI850	—	COMPLETED	2008-11	NCT00756548
Braintree Laboratories	BLI850	—	COMPLETED	2008-11	NCT00756977
Suzhou Suncadia Biopharmaceuticals Co., Ltd.	SHR-1701、 BP102 、XELOX	—	TERMINATED	2024-04-17	NCT04856787
G1 Therapeutics, Inc.	Trilaciclib	—	TERMINATED	2023-02-13	NCT04607668
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	KL-140	—	TERMINATED	2021-11-27	NCT03426371
Egetis Therapeutics	Calmangafodipir (5 µmol/kg)	—	TERMINATED	2020-08-31	NCT04034355
Egetis Therapeutics	Calmangafodipir (2 µmol/kg)	—	TERMINATED	2020-08-31	NCT03654729
AB Science	Masitinib (AB1010)	—	TERMINATED	2017-12	NCT02605044
Johnson & Johnson	Xilonix	—	TERMINATED	2017-06-30	NCT01767857
HiberCell, Inc.	Imprime PGG + cetuximab	—	TERMINATED	2017-02	NCT01309126
Symphogen A/S	Sym004	—	WITHDRAWN	2023-12	NCT03717038
Mirror Biologics, Inc.	AlloStim®	—	WITHDRAWN	2019-12	NCT01741038
Roche	bevacizumab [Avastin]	—	WITHDRAWN	2015-05	NCT01338558

Showing 100 of 407 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
PMV Pharmaceuticals, Inc	rezatapopt	—	RECRUITING	2026-08-15	NCT04585750
MediLink Therapeutics (Suzhou) Co., Ltd.	YL202	—	RECRUITING	2026-08-31	NCT07202364
Kahr Bio Australia Pty Ltd	DSP107 + Atezolizumab	—	RECRUITING	2026-09-30	NCT07235293
Suzhou Teligene Ltd.	TL938 Capsules	—	RECRUITING	2026-10	NCT06589830
BeyondBio Inc.	BEY1107	—	RECRUITING	2026-11-30	NCT05093907
858 Therapeutics, Inc.	ETX-19477	—	RECRUITING	2026-12	NCT06395519
Artios Pharma Ltd	ART0380	—	RECRUITING	2026-12	NCT04657068
Delcath Systems Inc.	Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab	—	RECRUITING	2026-12	NCT06607458
One-carbon Therapeutics AB	TH9619	—	RECRUITING	2026-12	NCT07151040
Lumicell, Inc.	LUM015	—	RECRUITING	2026-12	NCT02584244
Sichuan Baili Pharmaceutical Co., Ltd.	SI-B003	—	RECRUITING	2026-12	NCT06008054
TiumBio Co., Ltd.	TU2218 + KEYTRUDA® (Pembrolizumab)	—	RECRUITING	2026-12	NCT05784688
Shanghai Henlius Biotech	HLX43 Dose 1;	—	RECRUITING	2026-12-30	NCT07106892
Jazz Pharmaceuticals	Zanidatamab	—	RECRUITING	2026-12-31	NCT06695845
Shanghai Pharmaceuticals Holding Co., Ltd	SPH5030	—	RECRUITING	2026-12-31	NCT06434597
IDEAYA Biosciences	IDE196	—	RECRUITING	2027-01-29	NCT03947385
Neonc Technologies, Inc.	NEO212 Oral Capsule	—	RECRUITING	2027-02-28	NCT06047379
Beijing Biotech	EB-DUO-CAR-NK-CEA/GCC	—	RECRUITING	2027-03-14	NCT07589517
NGM Biopharmaceuticals, Inc	NGM120 Q4W	—	RECRUITING	2027-04	NCT07033026
Apollo Therapeutics Ltd	APL-5125	—	RECRUITING	2027-04	NCT06399757
CuraCell TX AB	CC-38	—	RECRUITING	2027-04	NCT07255664
Parabilis Medicines, Inc.	FOG-001	—	RECRUITING	2027-04-01	NCT05919264
Johnson & Johnson	Amivantamab IV	—	RECRUITING	2027-04-27	NCT05379595
Revolution Medicines, Inc.	RMC-6236	—	RECRUITING	2027-05-15	NCT06445062
AstraZeneca	Volrustomig	—	RECRUITING	2027-05-31	NCT06792695
Revolution Medicines, Inc.	RMC-6236	—	RECRUITING	2027-05-31	NCT05379985
ITM Oncologics GmbH	[68Ga]Ga-DPI-4452	—	RECRUITING	2027-06	NCT05706129
Crossignal Therapeutics, Inc.	CT3001	—	RECRUITING	2027-06-20	NCT06598007
Genfleet Therapeutics (Shanghai) Inc.	—	—	RECRUITING	2027-07	NCT07259590
Shanghai JMT-Bio Inc.	JMT203 Injection	—	RECRUITING	2027-08-14	NCT06868849
Oncolytics Biotech	Bevacizumab	Vascular Endothelial Growth Factor Inhibitor [EPC]	RECRUITING	2027-08-30	NCT07446322
Stingray Therapeutics	SR-8541A	—	RECRUITING	2027-09	NCT06589440
Frontier Medicines Corporation	FMC-376	—	RECRUITING	2027-10	NCT06244771
AstraZeneca	Datopotamab deruxtecan (Dato-DXd)	—	RECRUITING	2027-10-01	NCT05489211
Radiopharm Theranostics, Ltd	177Lu-BetaBart	—	RECRUITING	2027-12	NCT07189871
Carina Biotech Limited	CNA3103: 5 x 10^7 cells	—	RECRUITING	2027-12	NCT05759728
Riboscience, LLC.	RBS2418	—	RECRUITING	2027-12	NCT06824064
Neogap Therapeutics AB	pTTL	—	RECRUITING	2027-12	NCT05908643
Beijing Biotech	EB-DUO-CAR-NK-CEA/GCC (IV)	—	RECRUITING	2027-12-21	NCT07462650
Shanghai EpimAb Biotherapeutics Co., Ltd.	EMB-01 1600 mg administered once weekly throughout the study	—	RECRUITING	2027-12-30	NCT07314294
7 Hills Pharma, LLC	Alintegimod	—	RECRUITING	2027-12-31	NCT06362369
Criterium, Inc.	Fruquintinib+ Lonsurf (trifluridine and tipiracil)	—	RECRUITING	2027-12-31	NCT06992258
Auricula Biosciences Inc.	WEF-001	—	RECRUITING	2028-01	NCT07148128
Perspective Therapeutics	[203Pb]Pb-PSV359	—	RECRUITING	2028-01-31	NCT06710756
Blue Earth Diagnostics	[18F]FPyQCP	—	RECRUITING	2028-01-31	NCT07432633
Ono Pharmaceutical Co., Ltd.	ONO-4578	—	RECRUITING	2028-02-15	NCT06948448
AbbVie	Telisotuzumab Adizutecan	—	RECRUITING	2028-03	NCT06820463
Anbogen Therapeutics, Inc.	ABT-301	—	RECRUITING	2028-04	NCT07244705
Betta Pharmaceuticals Co., Ltd.	MCLA-129	—	RECRUITING	2028-04-30	NCT04930432
Lyell Immunopharma, Inc.	LYL273	—	RECRUITING	2028-06	NCT05319314
A2 Biotherapeutics Inc.	A2B694	—	RECRUITING	2028-06	NCT06051695
Brenus Pharma	STC-1010 + IS regimen + SOC therapy	—	RECRUITING	2028-06	NCT06934538
ModeX Therapeutics, An OPKO Health Company	MDX2001	—	RECRUITING	2028-08	NCT06239194
Bristol-Myers Squibb	BMS-986523	—	RECRUITING	2028-10-13	NCT07223047
Isofol Medical AB	Arfolitixorin	—	RECRUITING	2028-11-30	NCT06922383
Revolution Medicines, Inc.	Elironrasib	—	RECRUITING	2028-12	NCT06128551
Verastem, Inc.	VS-7375	—	RECRUITING	2028-12	NCT07020221
Gilead	Denikitug	—	RECRUITING	2028-12	NCT07527858
Tubulis GmbH	TUB-030	—	RECRUITING	2028-12	NCT06657222
Boehringer Ingelheim	Zongertinib	Kinase Inhibitor [EPC]	RECRUITING	2029-01-08	NCT06324357
Eikon Therapeutics	EIK1005	—	RECRUITING	2029-03	NCT07262619
A2 Biotherapeutics Inc.	A2B395	—	RECRUITING	2029-03-31	NCT06682793
Alentis Therapeutics AG	ALE.P03	—	RECRUITING	2029-04-05	NCT07169734
Revolution Medicines, Inc.	Daraxonrasib	—	RECRUITING	2029-05	NCT07397338
Shenzhen Ionova Life Sciences Co., Ltd.	INV-8989	—	RECRUITING	2029-05	NCT07610798
MBrace Therapeutics	ADC	—	RECRUITING	2029-09-30	NCT07145255
Merck	Sacituzumab tirumotecan	—	RECRUITING	2029-10-16	NCT06428409
AbbVie	Telisotuzumab Adizutecan	—	RECRUITING	2029-11	NCT07023289
Hansoh BioMedical R&D Company	Cohort 1: HS-20110+ Bevacizumab+5-FU/leucovorin	—	RECRUITING	2029-12-31	NCT07283367
BioNTech SE	BNT314	—	RECRUITING	2030-12	NCT07079631
Bristol-Myers Squibb	BMS-986340	—	RECRUITING	2031-08-31	NCT04895709
Suzhou Suncadia Biopharmaceuticals Co., Ltd.	SHR-8068 Injection	—	RECRUITING	2031-10	NCT07071714
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	TQB2922 injection ± TAS-102 tablets	—	RECRUITING	2026-07	NCT07044908
Medicenna Therapeutics, Inc.	MDNA11	—	RECRUITING	2026-06-30	NCT05086692
Bold Therapeutics, Inc.	BOLD-100 +/- FOLFOX Chemotherapy (Arm VII)	—	RECRUITING	2026-06-01	NCT04421820
Portage Biotech	TT-10	—	RECRUITING	2026-06-01	NCT04969315
Buzzard Pharmaceuticals	isunakinra	—	RECRUITING	2026-06	NCT06634875
Chimeric Therapeutics	CHM-2101 CAR-T cells	—	RECRUITING	2026-05	NCT06055439
NanoEcho AB	Iron oxide nanoparticles	—	RECRUITING	2026-05	NCT06693375
Guangzhou JOYO Pharma Co., Ltd	JYP0015	—	RECRUITING	2026-03-30	NCT06895031
Apollomics Inc.	APL-101 Oral Capsules	—	RECRUITING	2026-03-30	NCT03175224
Innovent Biologics (Suzhou) Co. Ltd.	IBI363	—	RECRUITING	2026-03-01	NCT06281678
Allist Pharmaceuticals, Inc.	JAB-21822	—	RECRUITING	2026-03	NCT05288205
Alethia Biotherapeutics	Sotevtamab	—	RECRUITING	2026-03	NCT06225843
Chongqing Precision Biotech Co., Ltd	CEA-targeted CAR-T cells	—	RECRUITING	2025-12-31	NCT06006390
Zhejiang Yangli Pharmaceutical Technology Co., Ltd.	VB15010	—	RECRUITING	2025-12-30	NCT06819215
STCube, Inc.	Nelmastobart 800 mg+Trifluridine/Tipiracil+ Bevacizumab	—	RECRUITING	2025-12	NCT06873763
GI Innovation, Inc.	GI-102 subcutaneous (SC)	—	RECRUITING	2025-11-12	NCT05824975
Lantheus Medical Imaging	—	—	RECRUITING	2025-11	NCT06298916
Merus B.V.	MCLA-158	—	RECRUITING	2025-11	NCT03526835
Evopoint Biosciences Inc.	XNW27011	—	RECRUITING	2025-06-30	NCT06792435
Vyriad, Inc.	VV1	—	RECRUITING	2025-06	NCT04291105
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.	SSGJ-707	—	RECRUITING	2025-06	NCT06493760
GeneMedicine Co., Ltd.	GM103 (Part A)	—	RECRUITING	2025-05-30	NCT06265025
Jubaan Ltd.	—	—	RECRUITING	2025-03-30	NCT06612281
Suzhou Suncadia Biopharmaceuticals Co., Ltd.	SHR-1701；Capecitabine；Oxaliplatin	—	RECRUITING	2024-07-31	NCT05300269
Novartis	JDQ443	—	ACTIVE NOT RECRUITING	2026-09-30	NCT05358249
BioNTech SE	RO7198457 intravenous (IV)	—	ACTIVE NOT RECRUITING	2026-11	NCT04486378
Elicio Therapeutics	ELI-002 7P	—	ACTIVE NOT RECRUITING	2026-11	NCT05726864
Cardiff Oncology	Onvansertib	—	ACTIVE NOT RECRUITING	2026-11	NCT06106308

Showing 100 of 307 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Sichuan Baili Pharmaceutical Co., Ltd.	BL-M17D1	—	RECRUITING	2026-08	NCT06500052
Angiex, Inc.	AGX101	—	RECRUITING	2026-09-06	NCT06440005
EMD Serono Research & Development Institute, Inc.	M9140	—	RECRUITING	2026-10-23	NCT05464030
Hansoh BioMedical R&D Company	HS-20093	—	RECRUITING	2026-10-31	NCT06825624
Zumutor Biologics Inc.	ZM008	—	RECRUITING	2026-12	NCT06451497
Context Therapeutics Inc.	CT-95	—	RECRUITING	2026-12	NCT06756035
Monopar Therapeutics	MNPR-101-PCTA-177Lu	—	RECRUITING	2026-12	NCT06617169
RasCal Therapeutics, Inc.	RSC-1255 Dose Escalation	—	RECRUITING	2026-12-15	NCT04678648
Akamis Bio	NG-350A IV administration	—	RECRUITING	2026-12-30	NCT06459869
Medigen Biotechnology Corporation	Magicell-NK contains NK cells suspended in 100 mL normal saline	—	RECRUITING	2026-12-31	NCT05394714
Revolution Medicines, Inc.	RMC-9805	—	RECRUITING	2026-12-31	NCT06040541
Bicara Therapeutics	BCA101	—	RECRUITING	2026-12-31	NCT04429542
Chongqing Precision Biotech Co., Ltd	CEA-targeted CAR-T cells	—	RECRUITING	2026-12-31	NCT06043466
Orano Med Theranostics, SAS	²¹²Pb-DOTAM-GRPR1	—	RECRUITING	2027-01	NCT05283330
Kura Oncology, Inc.	Darlifarnib	—	RECRUITING	2027-01	NCT06026410
ViroMissile, Inc.	IDOV-Immune (oncolytic vaccinia virus)	—	RECRUITING	2027-01-31	NCT06910657
Valo Therapeutics Oy	PeptiCRAd-1	—	RECRUITING	2027-04-30	NCT05492682
Sairopa B.V.	ADU-1805	—	RECRUITING	2027-05	NCT05856981
Vividion Therapeutics, Inc.	VVD-133214	—	RECRUITING	2027-05-31	NCT06004245
ALX Oncology Inc.	ALX2004	—	RECRUITING	2027-06	NCT07085091
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.	Drug: IBI3028	—	RECRUITING	2027-06-30	NCT07589205
AbbVie	Azirkitug	—	RECRUITING	2027-07	NCT05005403
IDEAYA Biosciences	IDE034	—	RECRUITING	2027-07-30	NCT07503808
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)	BBO-11818	—	RECRUITING	2027-08	NCT06917079
Pheon Therapeutics	PHN-012	—	RECRUITING	2027-09	NCT07127874
KaliVir Immunotherapeutics	VET3-TGI	—	RECRUITING	2027-09-30	NCT06444815
MOMA Therapeutics	MOMA-341	—	RECRUITING	2027-11	NCT06974110
Iambic Therapeutics, Inc	IAM1363	—	RECRUITING	2027-12	NCT06253871
Sutro Biopharma, Inc.	STRO-004	—	RECRUITING	2027-12	NCT07227168
Jiangsu Simcere Pharmaceutical Co., Ltd.	SIM0610 for Injection	—	RECRUITING	2027-12	NCT07348211
Fate Therapeutics	FT836	—	RECRUITING	2028-01	NCT07216105
Novartis	68Ga-DFC413	—	RECRUITING	2028-01-22	NCT07630961
Chongqing Precision Biotech Co., Ltd	CEA-targeted CAR-T cells	—	RECRUITING	2028-03-31	NCT07179692
Revolution Medicines, Inc.	RMC-5127	—	RECRUITING	2028-04	NCT07349537
Pfizer	PF-07799933	—	RECRUITING	2028-04-23	NCT05355701
MacroGenics	MGC026 Dose Escalation	—	RECRUITING	2028-05	NCT06242470
ImmVirx Pty Ltd	IVX037	—	RECRUITING	2028-06-30	NCT05427487
Epkin	OKN4395	—	RECRUITING	2028-07	NCT06789172
Roche	Enzelkitug	—	RECRUITING	2028-07-31	NCT05581004
PAQ Therapeutics, Inc.	PT0511	—	RECRUITING	2028-10-18	NCT07300150
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)	BBO-10203	—	RECRUITING	2028-11	NCT06625775
Astellas	ASP5834	—	RECRUITING	2028-11-30	NCT07094204
Alpha-9 Oncology USA Inc.	[177Lu]Lu-A9-0631	—	RECRUITING	2028-12	NCT07661641
Immunome, Inc.	IM-1617	—	RECRUITING	2029-01	NCT07578571
Avacta Life Sciences Ltd	AVA6103	—	RECRUITING	2029-01	NCT07454642
Eli Lilly	LY3962673	—	RECRUITING	2029-03	NCT06586515
Cartography Biosciences	CBI-1214	—	RECRUITING	2029-04	NCT07321106
Pfizer	PF-08032562	—	RECRUITING	2029-04-14	NCT07318805
Alterome Therapeutics, Inc.	ALTA3263	—	RECRUITING	2029-05	NCT06835569
ArriVent BioPharma, Inc.	MRG007	—	RECRUITING	2029-05	NCT07066657
Novartis	68Ga-NNS309	—	RECRUITING	2029-05-09	NCT07261631
Kumquat Biosciences Inc.	KQB365	—	RECRUITING	2029-06-30	NCT06720987
Exelixis	Zanzalintinib	—	RECRUITING	2030-06-28	NCT05176483
Roche	Inavolisib	Kinase Inhibitor [EPC]	RECRUITING	2030-08-31	NCT04929223
Novartis	[68Ga]Ga-NNS309	—	RECRUITING	2031-01-15	NCT06562192
Roche	SPLIT Abs	—	RECRUITING	2034-02-12	NCT07416552
Dispatch Biotherapeutics	DISP-10	—	RECRUITING	2046-04	NCT07544589
Sapience Therapeutics	ST316	—	RECRUITING	2026-05-31	NCT05848739
Qilu Pharmaceutical Co., Ltd.	QLC1101	—	RECRUITING	2026-05-31	NCT06403735
R-Pharm	RPH-030	—	RECRUITING	2026-05-15	NCT07543744
JiaRay Group	JR8603	—	RECRUITING	2026-05	NCT06783569
Taiho Pharmaceutical Co., Ltd.	AB122	—	RECRUITING	2026-05	NCT04999761
Jiangsu Hansoh Pharmaceutical Co., Ltd.	HS-10502	—	RECRUITING	2026-04-01	NCT05740956
Monopar Therapeutics	MNPR-101-DFO*-89Zr	—	RECRUITING	2026-04	NCT06337084
Hansoh BioMedical R&D Company	HS-20117 combined HS-20093	—	RECRUITING	2026-03-30	NCT06621563
Chongqing Precision Biotech Co., Ltd	CEA-targeted CAR-T cells	—	RECRUITING	2025-12-31	NCT06126406
Chongqing Precision Biotech Co., Ltd	CEA CAR-T cells	—	RECRUITING	2025-12-31	NCT06010862
Rgenta Therapeutics Inc	RGT-61159	—	RECRUITING	2025-12	NCT06462183
Light Chain Bioscience - Novimmune SA	Biological NILK-2301	—	RECRUITING	2025-10	NCT06663839
Beijing Immunochina Medical Science & Technology Co., Ltd.	IM96 CAR-T Cells	—	RECRUITING	2025-08-15	NCT06718738
BioEclipse Therapeutics	CRX100 suspension for infusion	—	RECRUITING	2025-08	NCT04282044
Celyad Oncology SA	CYAD-101	—	RECRUITING	2023-08-21	NCT04991948
Celyad Oncology SA	CYAD-101	—	RECRUITING	2021-11-28	NCT03692429
OncoC4, Inc.	AI-061	—	ACTIVE NOT RECRUITING	2026-07-31	NCT05858736
Exelixis	XL092	—	ACTIVE NOT RECRUITING	2026-08-31	NCT03845166
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany	M9140	—	ACTIVE NOT RECRUITING	2026-09-30	NCT06806046
IDEAYA Biosciences	IDE-161	—	ACTIVE NOT RECRUITING	2026-10	NCT05787587
Novartis	DKY709	—	ACTIVE NOT RECRUITING	2026-10-30	NCT03891953
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair	CEA protein antigen plus BCG Vaccine Mix for percutaneous use	—	ACTIVE NOT RECRUITING	2026-11-28	NCT02403505
HiFiBiO Therapeutics	HFB200603	—	ACTIVE NOT RECRUITING	2026-12	NCT05789069
Pfizer	Tucatinib	Kinase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2026-12-31	NCT05382364
AgonOx, Inc.	DP CD8 TIL	—	ACTIVE NOT RECRUITING	2026-12-31	NCT05902520
HUYABIO International, LLC.	HBI-2438	—	ACTIVE NOT RECRUITING	2026-12-31	NCT05485974
HUYABIO International, LLC.	HBI-2376	—	ACTIVE NOT RECRUITING	2026-12-31	NCT05163028
Enliven Therapeutics	ELVN-002	—	ACTIVE NOT RECRUITING	2027-01	NCT06328738
NeoTX Therapeutics Ltd.	—	—	ACTIVE NOT RECRUITING	2027-03-01	NCT03983954
Revolution Medicines, Inc.	RMC-6291	—	ACTIVE NOT RECRUITING	2027-03-31	NCT05462717
Novartis	HRO761	—	ACTIVE NOT RECRUITING	2027-08-31	NCT05838768
Ono Pharmaceutical Co., Ltd.	ONO-4578	—	ACTIVE NOT RECRUITING	2027-10-31	NCT06547385
AbbVie	ABBV-400	—	ACTIVE NOT RECRUITING	2027-11	NCT05029882
AbbVie	Telisotuzumab Adizutecan	—	ACTIVE NOT RECRUITING	2027-12	NCT06464692
Roche	GDC-6036	—	ACTIVE NOT RECRUITING	2027-12-31	NCT04449874
Ono Pharmaceutical Co., Ltd.	ONO-7913	—	ACTIVE NOT RECRUITING	2027-12-31	NCT06540261
Eli Lilly	LY4066434.	—	ACTIVE NOT RECRUITING	2030-01	NCT06607185
TORL Biotherapeutics, LLC	TORL-3-600	—	ACTIVE NOT RECRUITING	2026-06-25	NCT05948826
Toray Industries, Inc	TRK-950	—	ACTIVE NOT RECRUITING	2026-06	NCT03872947
Poseida Therapeutics, Inc.	P-MUC1C-ALLO1 CAR-T cells	—	ACTIVE NOT RECRUITING	2026-04	NCT05239143
Harbour BioMed (Guangzhou) Co. Ltd.	HBM4003	—	ACTIVE NOT RECRUITING	2025-09-30	NCT05167071
Wugen, Inc.	WU-NK-101 - Dose Escalation	—	ACTIVE NOT RECRUITING	2025-09-30	NCT05674526
DEKA Biosciences	DK210 (EGFR)	—	ACTIVE NOT RECRUITING	2025-07	NCT05704985

Precision Medicine Biomarkers

All biomarkers →

Biomarkers used for patient selection in Colorectal Cancer

HER2 (20) VEGF (17) RET (12) EGFR- (8) NTRK (8) FGFR (8)

Novel Colorectal Cancer Drugs by Company (New molecular entities)

8 companies have an FDA-approved novel drug for Colorectal Cancer.

Bristol-Myers Squibb 3 drugs

Roche 1 drug

Sanofi 1 drug

Takeda 1 drug

Eli Lilly 1 drug

SEAGEN 1 drug

IMCLONE 1 drug

Merck 1 drug

Colorectal Cancer Drug Targets

Molecular targets of approved and investigational Colorectal Cancer drugs — 14 targets tracked.

PDCD1 3 VEGFA 3 Thymidylate Synthase 2 Dihydrofolate reductase 1 Hyaluronan 1 PlGF 1 VEGF-B 1 CTLA4 1 VEGFR-1 1 VEGFR-2 1 VEGFR-3 1 VEGFR2 1 ERBB2 1 EGFR 1

Biosimilars (1 BLA approved) Click to expand

Biosimilars are biological products highly similar to FDA-approved reference biologics with no clinically meaningful differences in safety, purity, or potency.

ALYMSYS

AMNEAL PHARMS

2022

Generic Drugs (2 ANDA approved) Click to expand

Generic drugs contain the same active ingredient as the brand-name drug and are approved via ANDA (Abbreviated New Drug Application).

CAPECITABINE

SHILPA

LEVOLEUCOVORIN CALCIUM

MEITHEAL

Related Indications

Other Oncology indications

View all Oncology

Drug Categories:

Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
Biosimilars: BLA-approved biologics highly similar to reference products
Generics: ANDA-approved copies of small molecule drugs

View data sources and methodology